SCHEMBL4055971

SCHEMBL4055971

COc1cccc(-c2cnc3nc(-c4ccccc4OC)[nH]c3c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 4/20 0.56
PDE5A O76074 4/20 0.56
PDGFRB P09619 2/20 0.53
PDGFRA P16234 2/20 0.53
PDE2A O00408 1/20 0.52
NOS3 P29474 1/20 0.47
NOS1 P29475 1/20 0.47
NOS2 P35228 1/20 0.47
FYN P06241 1/20 0.46
NR1I2 O75469 1/20 0.45
CYP1A2 P05177 1/20 0.45
VDR P11473 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2B6 P20813 1/20 0.45
AHR P35869 1/20 0.45
NR1I3 Q14994 1/20 0.45
KIT P10721 1/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4059875 0.89 PDE5A (0.62) AURKAPDE5APDGFRBPDGFRAPDE2A
SCHEMBL4051873 0.88 AURKA (0.53) AURKAPDGFRBPDGFRAPDE2ANOS3
SCHEMBL4059434 0.87 AURKA (0.63) AURKANOS3NOS1NOS2NR1I2
SCHEMBL4062482 0.87 AURKA (0.70) AURKAPDGFRBPDGFRANOS3NOS1
SCHEMBL4053263 0.85 PDE5A (0.52) AURKAPDE5APDGFRBPDGFRAPDE2A
SCHEMBL4055330 0.84 AURKA (0.67) AURKANOS3NOS1NOS2NR1I2
SCHEMBL4052372 0.83 AURKA (0.69) AURKASMN1; SMN2IKBKETBK1AURKB
SCHEMBL4060342 0.83 PDE5A (0.57) AURKAPDE5APDGFRBPDGFRAPDE2A
SCHEMBL4058200 0.83 AURKA (0.58) AURKAPDGFRBPDGFRANOS3NOS1
SCHEMBL4054258 0.82 AURKA (0.49) AURKAPDE5APDGFRBPDGFRANR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B AURKA 247/4885PDE5A 2762/4885PDGFRB 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.